The COVID-19 vaccine landscape is gradually becoming more diverse. And it could grow more so, as several companies work on intranasal vaccines.
Intranasal vaccines offer potential advantages over traditional intramuscular vaccines. They can stimulate immunoglobulin A production, which can avert infection, as a recent Scientific American article noted.
Get the full story from our sister site, Drug Discovery & Development.